Financial updates
Pharming Reports on Financial Results for the First Half of 2018
Pharming Group N.V. presents its (unaudited) financial report for the six months ended 30 June 2018.
- Record revenue from product sales, up 96% on 2017
- Pharming’s first half year of net profitability
- Expanding pipeline of new products plus new large indications and dosage forms for RUCONEST®
“We are delighted with the further progress we have made expanding the reach of RUCONEST®, allowing more patients to access the clinical benefits of our product.”
- Sijmen de Vries - CEO